00:00It's Benzinga, bringing Wall Street to Main Street.
00:02President Trump signed an executive order on Saturday to accelerate research on psychedelics
00:07such as psilocybin, MDMA, and Ibogaine, according to CNBC. The order directs the U.S. Food and
00:14Drug Administration to expand clinical trials and right-to-try access for patients with serious
00:20mental health conditions while leaving drug scheduling unchanged. The move follows a prior
00:25effort to reschedule cannabis that has stalled in review. Stocks tied to psychedelics developers
00:30rose with a Tybeckley up about 25% Monday and gains across Compass Pathways, Difinium Therapeutics,
00:36and Siben. Industry leaders said the order signals legitimacy and is meaningful,
00:41but its impact depends on execution through rigorous science,
00:44safety standards, and real-world clinical outcomes. For all things money, visit Benzinga.com.
Comments